Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
04 October 2022 | Story Samkelo Fetile | Photo Supplied
Dr Sevias Guvurio
Dr Sevias Guvuriro.

Dr Sevias Guvuriro from the Faculty of Economic and Management Sciences at the University of the Free State (UFS) is the first UFS candidate to participate in the University of Michigan African Presidential Scholarship (UMAPS) fellowship programme. Dr Guvuriro is also a member of the Future Professoriate Group participating in the Transformation of the Professoriate Programme.  

About the project 

Dr Guvuriro’s main project during his five-month stay at the University of Michigan was on hazardous drinking and economic preferences among urban youth in South Africa. The project recognises that lifestyle behaviours in early life are important drivers of chronic disease later in life, and that harmful use of alcohol is among the main risk factors for non-communicable diseases in the world. According to Dr Guvuriro, persuasive behaviour-change approaches could be useful, especially in the context of developing countries, where the World Health Organisation’s non-communicable diseases ‘Best Buys’ interventions on alcohol use could be ineffective. Behavioural economics and experimental economics techniques could also be beneficial. "With the assistance of my host, Prof Erin Krupka from the University of Michigan School of Information, academics and other staff members, I have made very strong progress in analysing my survey and experimental data on the subject, which I obtained here in South Africa,” said Dr Guvuriro.

Unpacking UMAPS 

UMAPS offers African scholars drawn from across Africa the opportunity to spend five months at the University of Michigan, working and interacting with faculty members who are leaders in their fields. Each year, applications for the fellowship open on 15 August and close on 15 October. The programme started in 2009, hosting a single cohort each year. From 2020, the programme hosted two cohorts of about 15 African scholars each. These scholars are selected annually from an application pool of about 600. 

"It was an amazing experience, one that I wish all of my colleagues in the faculty and the institution at large could have," Dr Guvuriro said. “Other than meeting the faculty staff at the University of Michigan – who are amazing – I got to meet and interact with world leaders in the economics subdiscipline of my interest.” 

He concluded by stating that this is a rare opportunity for scholars, and although competitive, he believes it is worth applying for. “Although I was the first from the UFS to attend, I know that the August to December 2022 cohort has another UFS staff member, which is great. My wish would be for our university to be represented annually.”

News Archive

#Women'sMonth: Save the children
2017-08-10

Description: Trudi O'Neill Tags: : rotaviruses, young children, Dr Trudi O’Neill, Department of Microbial, Biochemical and Food Biotechnology, vaccine 

Dr Trudi O’Neill, Senior lecturer in the Department of
Microbial, Biochemical and Food Biotechnology.
Photo: Anja Aucamp

Dr Trudi O’Neill, Senior lecturer in the Department of Microbial, Biochemical and Food Biotechnology, is conducting research on rotavirus vaccines.

Dr O’Neill was inspired to conduct research on this issue through her fascination with the virus. “The biology of rotaviruses, especially the genome structure and the virus’ interaction with the host, is fascinating.”

“In fact, it is estimated that, globally, ALL children will be infected with rotavirus before the age of five, irrespective of their socio-economic standing. However, infants and young children in poor countries are more vulnerable due to inadequate healthcare. The WHO estimates that approximately 215 000 deaths occur each year. This roughly equates to eight Airbus A380 planes, the largest commercial carrier with a capacity of approximately 500 seats, filled with only children under the age of five, crashing each week of every year.”

Alternative to expensive medicines 
“Currently, there are two vaccines that have been licensed for global use. However, these vaccines are expensive and poor countries, where the need is the greatest, are struggling to introduce them sustainably. It is therefore appealing to study rotaviruses, as it is scientifically challenging, but could at the same time have an impact on child health,” Dr O’Neill said.

The main focus of Dr O’Neill’s research is to develop a more affordable vaccine that can promote child vaccination in countries/areas that cannot afford the current vaccines.

All about a different approach 

When asked about the most profound finding of her research, Dr O’Neill responded: “It is not so much a finding, but rather the approach. My rotavirus research group is making use of yeast as vehicle to produce a sub-unit vaccine. These microbes are attractive, as they are relatively easy to manipulate and cheap to cultivate. Downstream production costs can therefore be reduced. The system we use was developed by my colleagues, Profs Koos Albertyn and Martie Smit, and allows for the potential use of any yeast. This enables us to screen a vast number of yeasts in order to identify the best yeast producer.”

Vaccination recently acquired a bad name in the media for its adverse side effects. As researcher, Dr O’Neill has this to say: “Vaccines save lives. By vaccinating your child, you don’t just protect your own child from a potentially deadly infection, but also other children in your community that might be too young to be vaccinated or have pre-existing health problems that prevents vaccination.” 

A future without rotavirus vaccination?

Dr O’Neill believes a future without rotavirus vaccination will be a major step backwards, as the impact of rotavirus vaccines has been profound. “Studies in Mexico and Malawi actually show a reduction in deaths. A colleague in Mozambique has commented on the empty hospital beds that amazed both clinicians and scientists only one year after the introduction of the vaccine in that country. Although many parents, mostly in developed countries, don’t have to fear dehydrating diarrhoea and potential hospitalisation of their babies due to rotavirus infection anymore, such an infection could still be a death sentence in countries that have not been able to introduce the vaccine in their national vaccination programmes,” she said. 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept